TY - JOUR
T1 - Overexpression of p54nrb/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth
AU - Yamamoto, Ryuji
AU - Osawa, Tsuyoshi
AU - Sasaki, Yusuke
AU - Yamamoto, Shogo
AU - Anai, Motonobu
AU - Izumi, Kouji
AU - Matsumura, Yoshihiro
AU - Sakai, Juro
AU - Aburatani, Hiroyuki
AU - Mizokami, Atsushi
AU - Kodama, Tatsuhiko
AU - Tanaka, Toshiya
N1 - Funding Information:
This work was supported by the Project for Cancer Research And Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED).
Publisher Copyright:
© Yamamoto et al.
PY - 2018
Y1 - 2018
N2 - The non-POU domain-containing octamer binding protein p54nrb/NONO is a multifunctional nuclear protein involved in RNA splicing, processing, and transcriptional regulation of nuclear hormone receptors. Through chromosome copy number analysis via whole-exome sequencing, we revealed amplification of the chromosome Xq11.22-q21.33 locus containing the androgen receptor (AR) and NONO genes in androgen-independent, castration-resistant prostate cancer (CRPC)- like LNCaP-SF cells. Moreover, NONO was frequently amplified and overexpressed in patients with CRPC. RNA sequencing data revealed that a truncated ephrin type-A receptor 6 (EPHA6) splice variant (EPHA6-001) was overexpressed in LNCaP-SF cells, and knockdown of NONO or EPHA6-001 prevented EPHA6-001 expression and reduced proliferation and invasion by LNCaP-SF cells grown under androgen deprivation conditions. Growth inhibition and differential splicing of EPHA6 mRNA by p54nrb/ NONO were confirmed in gene silencing experiments in 22Rv1 PCa cells. Importantly, NONO knockdown in LNCaP-SF cells led to reduced tumor growth in castrated mice. These findings indicate that p54nrb/NONO is amplified and overexpressed in CRPC cells and clinical samples, and facilitates CRPC growth by mediating aberrant EPHA6 splicing. We therefore propose that p54nrb/NONO constitutes a novel and attractive therapeutic target for CRPC.
AB - The non-POU domain-containing octamer binding protein p54nrb/NONO is a multifunctional nuclear protein involved in RNA splicing, processing, and transcriptional regulation of nuclear hormone receptors. Through chromosome copy number analysis via whole-exome sequencing, we revealed amplification of the chromosome Xq11.22-q21.33 locus containing the androgen receptor (AR) and NONO genes in androgen-independent, castration-resistant prostate cancer (CRPC)- like LNCaP-SF cells. Moreover, NONO was frequently amplified and overexpressed in patients with CRPC. RNA sequencing data revealed that a truncated ephrin type-A receptor 6 (EPHA6) splice variant (EPHA6-001) was overexpressed in LNCaP-SF cells, and knockdown of NONO or EPHA6-001 prevented EPHA6-001 expression and reduced proliferation and invasion by LNCaP-SF cells grown under androgen deprivation conditions. Growth inhibition and differential splicing of EPHA6 mRNA by p54nrb/ NONO were confirmed in gene silencing experiments in 22Rv1 PCa cells. Importantly, NONO knockdown in LNCaP-SF cells led to reduced tumor growth in castrated mice. These findings indicate that p54nrb/NONO is amplified and overexpressed in CRPC cells and clinical samples, and facilitates CRPC growth by mediating aberrant EPHA6 splicing. We therefore propose that p54nrb/NONO constitutes a novel and attractive therapeutic target for CRPC.
KW - CRPC
KW - EPHA6
KW - Neuroendocrine prostate cancer
KW - P54nrb/NONO
KW - RNA splicing
UR - http://www.scopus.com/inward/record.url?scp=85041964977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041964977&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.24063
DO - 10.18632/oncotarget.24063
M3 - Article
C2 - 29535823
AN - SCOPUS:85041964977
SN - 1949-2553
VL - 9
SP - 10510
EP - 10524
JO - Oncotarget
JF - Oncotarget
IS - 12
ER -